Where to Start

Free Info Packet

Note: The use of the Internet for communications with the firm will not establish an attorney-client relationship and messages containing confidential or time-sensitive information should not be sent. I agree that submitting this form does not create an attorney-client relationship and that Seeger Weiss LLP, Flood Law Office, and Melinda J. Helbock, A.P.C. will use the information I am providing to check for conflicts of interest to determine if the firm can assist me with my legal inquiry. I Agree:*

Privacy protected. All information held in the strictest confidence.

Featured Expert: Daniel Powers, M.D. Board Certified Diagnostic Radiologist. Learn More

Mesothelioma Treatment

"FDA Approves New Drug for Mesothelioma Patients"

May 6, 2004
The FDA recently approved a new drug for the treatment of malignant pleural mesothelioma, a rare cancer normally linked to asbestos exposure.

The drug, Alimita (pemetrexed disodium), is distributed by Eli Lilly and Company. Alimita is intended for use in conjunction with cisplatin, another mesothelioma drug.

In a randomized clinical trial, patients receiving Alimita and cisplatin lived an average of one year after the start of the trial, while those taking only cisplatin lived an average of nine months.

Alimita must be supplemented with vitamin B-12 and folic acid to decrease the incidence and severity of adverse effects, which include low white blood count, nausea, vomiting, fatigue, rash and diarrhea. The drug also suppresses bone marrow; patients should immediately report any signs of infection, such as fever or chills.

Only about 2,000 new cases of mesothelioma are diagnosed annually in the United States. Patients live an average of nine to thirteen months following diagnosis.

More Asbestos Law News....

top of page